{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:23:19Z","timestamp":1794493399767,"version":"4.9.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010756","name":"Health and Social Care Research and Development Division","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.fertnstert.2025.03.011","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:27:38Z","timestamp":1742419658000},"page":"344-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of ovulation and pharmacologic mechanism of action of relugolix combination therapy"],"prefix":"10.1016","volume":"124","author":[{"given":"Ingrid J.M.","family":"Duijkers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Klipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Draeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Schug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph-Steven","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Camilo","family":"Arjona Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Migoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2025.03.011_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","article-title":"Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice","volume":"723","author":"Nakata","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib2","series-title":"Endotext. South Dartmouth (MA)","article-title":"Physiology of GnRH and gonadotropin secretion","author":"Marques","year":"2000"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib3","series-title":"MYFEMBREE prescribing information","volume":"Vol. 2023","year":"2022"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2021.750018","article-title":"Endometriosis and uterine fibroids (leiomyomata): comorbidity, risks and implications","volume":"3","author":"Uimari","year":"2021","journal-title":"Front Reprod Health"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib6","series-title":"Australian product information: RYEQO\u00ae 40\/1\/0.5 (relugolix, estradiol, norethisterone acetate) film-coated tablets","volume":"Vol. 2024","year":"2022"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40262-023-01269-9","article-title":"A randomized open-label study of relugolix alone or relugolix combination therapy in premenopausal women","volume":"62","author":"Lukes","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-016-2189-8","article-title":"Who is a \u2018healthy subject\u2019?-consensus results on pivotal eligibility criteria for clinical trials","volume":"73","author":"Breithaupt-Groegler","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","article-title":"Ultrasound evaluation of ovarian activity under oral contraceptives","volume":"47","author":"Hoogland","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0010-7824(80)90142-0","article-title":"Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration","volume":"21","author":"Landgren","year":"1980","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.contraception.2021.03.003","article-title":"Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function","volume":"103","author":"Duijkers","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3109\/13625187.2015.1074675","article-title":"Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1515\/CCLM.2006.160","article-title":"Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer","volume":"44","author":"Stricker","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib20","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz086","article-title":"Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women","volume":"105","author":"Archer","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-019-00840-7","article-title":"Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis","volume":"59","author":"Shebley","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib23","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-9378(90)90667-V","article-title":"Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis","volume":"163","author":"Friedman","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib26","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1038\/psp.2012.10","article-title":"Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis","volume":"1","author":"Riggs","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.fertnstert.2025.03.011_bib27","first-page":"73","article-title":"Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis","volume":"4","author":"Arjona Ferreira","year":"2023","journal-title":"F S Rep"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028225001591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028225001591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:07:56Z","timestamp":1791320876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028225001591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0015028225001591"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.03.011","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of ovulation and pharmacologic mechanism of action of relugolix combination therapy","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2025.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}